Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNA1H | O95180 | 11/20 | 0.70 |
| ▸ | CACNA1G | O43497 | 3/20 | 0.41 |
| ▸ | SCN7A | Q01118 | 4/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | SCN9A | Q15858 | 3/20 | 0.37 |
| ▸ | CNR1 | P21554 | 2/20 | 0.36 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.35 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.34 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.34 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.34 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.34 |
| ▸ | SCN8A | Q9UQD0 | 1/20 | 0.34 |
| ▸ | SCN10A | Q9Y5Y9 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15844077 | 0.90 | CACNA1H (0.56) | CACNA1HCACNA1GSCN7AKCNH2MEN1 | |
| SCHEMBL18761295 | 0.89 | CACNA1H (0.56) | CACNA1HCACNA1GSCN7AKCNH2MEN1 | |
| SCHEMBL15844275 | 0.88 | CACNA1H (0.54) | CACNA1HCACNA1GLMNATSHR | |
| SCHEMBL15844419 | 0.88 | CACNA1H (0.54) | CACNA1HCACNA1GSCN7AKCNH2LMNA | |
| SCHEMBL20094224 | 0.88 | CACNA1H (0.57) | CACNA1HSCN7AKCNH2MEN1KMT2A | |
| SCHEMBL18761313 | 0.86 | CACNA1H (0.53) | CACNA1HCACNA1GMEN1KMT2ALMNA | |
| SCHEMBL15844552 | 0.82 | CACNA1H (1.00) | CACNA1HCACNA1GCACNA1BCACNA1C | |
| Hydrochloric Acid SCHEMBL12495897 | 0.81 | CACNA1H (0.98) | CACNA1HCACNA1GCACNA1BCACNA1C | |
| SCHEMBL18761567 | 0.81 | CACNA1H (0.52) | CACNA1HCACNA1GSCN7AKCNH2SCN9A | |
| SCHEMBL3427756 | 0.78 | EGLN1 (0.42) | CACNA1HCACNA1GCACNA1BCACNA1C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10351514-B2 | Benzimidazole inhibitors of the sodium channel | Mark G. DeGiacomo, Interim Trustee (US) | 2019-07-16 | — | — | US | disclosed |
| US-10351514-B2 | Benzimidazole inhibitors of the sodium channel | Mark G. DeGiacomo, Interim Trustee (US) | 2019-07-16 | — | — | US | disclosed |
| US-20180111894-A1 | Benzimidazole Inhibitors of the Sodium Channel | DeGiacomo, Mark G. (US) | 2018-04-26 | — | — | US | disclosed |
| US-20180111894-A1 | Benzimidazole Inhibitors of the Sodium Channel | DeGiacomo, Mark G. (US) | 2018-04-26 | — | — | US | disclosed |
| US-20170260130-A1 | Benzimidazole Inhibitors of the Sodium Channel | DeGiacomo, Mark G. (US) | 2017-09-14 | — | — | US | disclosed |
| US-20170260130-A1 | Benzimidazole Inhibitors of the Sodium Channel | DeGiacomo, Mark G. (US) | 2017-09-14 | — | — | US | disclosed |
| US-9688615-B2 | Benzimidazole inhibitors of the sodium channel | DEGIACOMO, INTERIM TRUSTEE, MARK G. (US) | 2017-06-27 | — | — | US | disclosed |
| US-9688615-B2 | Benzimidazole inhibitors of the sodium channel | DEGIACOMO, INTERIM TRUSTEE, MARK G. (US) | 2017-06-27 | — | — | US | disclosed |
| EP-3009427-A1 | BENZIMIDAZOLE INHIBITORS OF THE SODIUM CHANNEL | Zalicus Pharmaceuticals Ltd. (CA) | 2016-04-20 | — | — | EP | disclosed |
| EP-3009427-A1 | BENZIMIDAZOLE INHIBITORS OF THE SODIUM CHANNEL | Zalicus Pharmaceuticals Ltd. (CA) | 2016-04-20 | — | — | EP | disclosed |
| US-20150361032-A1 | BENZIMIDAZOLE INHIBITORS OF THE SODIUM CHANNEL | NATIONAL CENTER FOR ADDICTION STUDIES AND TREATMENT FOUNDATION | 2015-12-17 | — | — | US | disclosed |
| US-20150361032-A1 | BENZIMIDAZOLE INHIBITORS OF THE SODIUM CHANNEL | NATIONAL CENTER FOR ADDICTION STUDIES AND TREATMENT FOUNDATION | 2015-12-17 | — | — | US | disclosed |
| US-20140187533-A1 | BENZIMIDAZOLE INHIBITORS OF THE SODIUM CHANNEL | ZALICUS PHARMACEUTICALS LTD. (CA) | 2014-07-03 | — | — | US | disclosed |
| US-20140187533-A1 | BENZIMIDAZOLE INHIBITORS OF THE SODIUM CHANNEL | ZALICUS PHARMACEUTICALS LTD. (CA) | 2014-07-03 | — | — | US | disclosed |
| US-20140187533-A1 | BENZIMIDAZOLE INHIBITORS OF THE SODIUM CHANNEL | ZALICUS PHARMACEUTICALS LTD. (CA) | 2014-07-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150361032-A1 | BENZIMIDAZOLE INHIBITORS OF THE SODIUM CHANNEL | SCN1A, KCNJ11, KCNJ1 | CACNA1H 67/4885CACNA1G 49/4885SCN7A 39/4885 |
| US-10351514-B2 | Benzimidazole inhibitors of the sodium channel | SCN1A, KCNJ11, KCNJ1 | CACNA1H 65/4885CACNA1G 38/4885SCN7A 33/4885 |
| US-20180111894-A1 | Benzimidazole Inhibitors of the Sodium Channel | SCN1A, KCNJ11, KCNJ1 | CACNA1H 65/4885CACNA1G 38/4885SCN7A 33/4885 |
| US-20170260130-A1 | Benzimidazole Inhibitors of the Sodium Channel | SCN1A, KCNJ11, KCNJ1 | CACNA1H 67/4885CACNA1G 49/4885SCN7A 39/4885 |
| US-20140187533-A1 | BENZIMIDAZOLE INHIBITORS OF THE SODIUM CHANNEL | SCN1A, KCNJ11, KCNJ1 | CACNA1H 66/4885CACNA1G 42/4885SCN7A 31/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.